A comprehensive systematic review and meta-analysis investigating acute minor ischemic stroke has found that intravenous alteplase does not produce a significant overall improvement in functional recovery compared with non-thrombolytic management, while substantially elevating the hazards of intracranial bleeding. Published in Frontiers in Neurology by researchers Yilin Zhang of the University of Leeds and Xinyue Shen of the Air Force Hospital of Western Theater Command in Chengdu, the synthesis evaluated data from 9,680 adult patients across sixteen reports representing eleven randomized controlled trials and prospective comparative cohort investigations. Minor ischemic stroke has historically presented a clinical dilemma because patients display mild initial neurological deficits, typically categorized as a baseline National Institutes of Health Stroke Scale score of five or lower, yet remain susceptible to neurological worsening, recurrent ischemic events, and lasting functional disability. Although intravenous alteplase serves as an established reperfusion therapy for acute ischemic stroke broadly, its targeted efficacy and safety profile in minor stroke presentations have remained intensely contested across clinical stroke care.
To rigorously examine this therapeutic balance, the investigators searched MEDLINE through OVID, Embase, and the Cochrane Library from database inception up to April 2026 without language restrictions, having prospectively registered their systematic review protocol in the PROSPERO database under identifier CRD420261394338. Eligible investigations were required to enroll adult patients presenting with acute minor ischemic stroke defined predominantly by a baseline stroke scale threshold of five or below, contrasting intravenous alteplase directly against non-thrombolytic comparator regimens such as standard stroke-unit medical care, dual antiplatelet therapy, aspirin, best medical management, or placebo. Studies utilizing alternative thrombolytic agents, purely retrospective cohorts lacking prospective data collection, single-arm series, bridging therapies, and endovascular thrombectomy protocols were systematically excluded to minimize bias. The final pooled dataset incorporated 3,664 patients who received intravenous alteplase and 6,016 control patients derived from four randomized controlled trials and seven prospective cohort studies conducted across China, Austria, the United States, Australia, Italy, and Spain.
The meta-analysis evaluated functional recovery primarily through the achievement of an excellent functional outcome, defined as a modified Rankin Scale score of zero to one measured at ninety days or three months following the qualifying stroke. Across ten studies reporting this primary endpoint, intravenous alteplase demonstrated no statistically significant association with enhanced recovery, yielding a pooled random-effects odds ratio of 1.05 with a 95 percent confidence interval spanning from 0.83 to 1.33 and an associated p-value of 0.67. Statistical heterogeneity across these evaluations remained relatively low at an I-squared value of twenty percent. Similarly, secondary assessment of good functional outcome, defined as reaching a modified Rankin Scale score between zero and two across four reporting studies, showed no notable difference between therapeutic cohorts, generating an odds ratio of 0.96 with a 95 percent confidence interval from 0.60 to 1.53 and an I-squared measure of three percent.
In stark contrast to the neutral functional recovery findings, safety evaluations revealed substantial and statistically significant increases in cerebral bleeding complications among patients receiving thrombolysis. Symptomatic intracranial hemorrhage, evaluated across seven investigations utilizing standardized definitions such as the European Cooperative Acute Stroke Study criteria, the National Institute of Neurological Disorders and Stroke criteria, SITS-MOST, or the Heidelberg Bleeding Classification, was markedly heightened following alteplase administration, producing a pooled odds ratio of 6.01 with a 95 percent confidence interval ranging from 2.60 to 13.89, an associated p-value below 0.001, and zero percent observed statistical heterogeneity. Furthermore, any intracranial hemorrhage, captured across eight studies, was significantly elevated among alteplase recipients, generating an odds ratio of 1.86 with a 95 percent confidence interval of 1.17 to 2.95 and a p-value of 0.009, with low heterogeneity recorded at seventeen percent.
The researchers also conducted detailed evaluations of additional critical clinical endpoints, documenting neutral outcomes across survival and recurring vascular manifestations. All-cause mortality across seven studies showed no statistically significant variation between alteplase and non-thrombolytic control treatment, registering an odds ratio of 0.77 with a 95 percent confidence interval of 0.39 to 1.52 and an I-squared value of zero percent. Similarly, recurrent stroke or recurrent ischemic stroke was evaluated across four reports, showing comparable distributions between treatment groups with a pooled odds ratio of 0.93, a 95 percent confidence interval of 0.43 to 2.02, and zero percent heterogeneity. Across five studies capturing early neurological deterioration, alteplase was not associated with an overall difference relative to control therapy, displaying an odds ratio of 1.24 with a 95 percent confidence interval of 0.67 to 2.27, although this specific outcome demonstrated substantial statistical heterogeneity with an I-squared value of sixty-one percent.
Prespecified subgroup analyses illuminated important divergences when patient groups were categorized by distinct clinical phenotypes and baseline characteristics. When stratifying by clinical presentation, alteplase provided no functional advantage in patients diagnosed with non-disabling or low-risk minor stroke, demonstrating an odds ratio of 0.85 with a 95 percent confidence interval of 0.64 to 1.14. Conversely, among cohorts presenting with mixed or higher-risk minor stroke presentations, alteplase administration was associated with significantly increased odds of achieving excellent functional recovery, generating an odds ratio of 1.28 with a 95 percent confidence interval of 1.01 to 1.62, yielding a statistically significant subgroup interaction p-value of 0.03. In contrast, further subgroup examinations categorized by baseline stroke scale thresholds of three or lower versus five or lower, comparator therapy types, and symptom-onset-to-treatment time windows revealed no significant subgroup divergences regarding functional recovery.
Exploratory subgroup investigations regarding early neurological deterioration similarly revealed notable variations across study parameters and comparator frameworks. Stratification demonstrated that alteplase was associated with an increased hazard of early neurological deterioration within studies focused strictly on non-disabling or low-risk minor stroke phenotypes, whereas this increased risk was absent among populations with mixed or higher-risk clinical profiles, yielding a subgroup interaction p-value of 0.008. Furthermore, studies comparing alteplase directly against active antiplatelet regimens exhibited an increased risk of early neurological deterioration relative to studies employing non-active or standard-care comparators, producing a statistically significant subgroup difference p-value of 0.003. When analyzed by initial neurological severity, studies applying a more restrictive baseline threshold of three or lower showed elevated deterioration risk with alteplase compared to studies enrolling patients with scores up to five, with a subgroup divergence p-value of 0.01.
Methodological quality assessments confirmed that the synthesized literature base maintained moderate to high rigor across study designs. Methodological evaluation of the four randomized controlled trials using the Cochrane Risk of Bias 2 tool classified one trial as having low risk of bias and three as displaying some concerns, which primarily originated from open-label operational designs, post hoc subgroup structures, or selective outcome reporting, with zero randomized studies judged as high risk. The seven prospective cohort studies assessed via the Newcastle-Ottawa Scale achieved scores between six and eight stars, reflecting solid prospective execution despite inherent observational limitations such as non-randomized allocation, potential confounding by indication, and occasional lack of blinded outcome assessment. Under Grading of Recommendations Assessment, Development and Evaluation criteria, the certainty of evidence was moderate for excellent functional outcome, symptomatic bleeding, and any intracranial hemorrhage, but low for good functional recovery, mortality, recurrent stroke, and early deterioration.
The authors contextualized their findings by exploring why overall thrombolytic functional improvements failed to materialize despite established biological reperfusion mechanisms. In major trials such as PRISMS and ARAMIS, a large proportion of control patients achieved excellent functional recovery at ninety days through standard medical or antiplatelet therapy alone, which substantially constrains the potential absolute margin for additional therapeutic benefit from thrombolysis. Furthermore, standard functional metrics such as dichotomized modified Rankin Scale scores of zero to one can exhibit reduced sensitivity in milder neurological impairments where patients already cluster near optimal recovery ceilings. Because individuals with minor deficits generally experience favorable trajectories, exposing an unselected minor stroke cohort to intravenous thrombolysis appears to introduce clear hemorrhagic hazards without delivering commensurate overall recovery gains, diluting potential therapeutic benefits that might otherwise exist in carefully selected higher-risk clinical subgroups.
The study authors highlighted several methodological limitations that warrant careful interpretation, including the relatively small overall count of eligible studies and modest absolute numbers of secondary safety events. Because randomized data frequently derived from post hoc subgroup extractions and observational cohorts inherently carry potential residual confounding, statistical homogeneity cannot be equated with absolute clinical uniformity. Additionally, operational definitions for early neurological deterioration, non-disabling symptoms, and symptomatic hemorrhage varied across historical trial protocols, and the subgroup analyses relied entirely on study-level characteristics rather than individual-patient datasets, exposing them to possible ecological bias. Consequently, the researchers concluded that current clinical evidence does not justify the routine application of intravenous alteplase across unselected patients presenting with acute minor ischemic stroke, advocating instead for individualized clinical assessments reserved for patients exhibiting distinct high-risk or disabling features.
Subject of Research: Efficacy and safety of intravenous alteplase in acute minor ischemic stroke
Article Title: Alteplase in minor ischemic stroke: a systematic review and meta-analysis of randomized and prospective studies
Article References: Zhang, Y., & Shen, X. (2026). Alteplase in minor ischemic stroke: a systematic review and meta-analysis of randomized and prospective studies. Frontiers in Neurology, 17, Article 1903094. https://doi.org/10.3389/fneur.2026.1903094
Image Credits: AI Generated
DOI: 10.3389/fneur.2026.1903094
Keywords: alteplase, minor ischemic stroke, systematic review, meta-analysis, intravenous thrombolysis, symptomatic intracranial hemorrhage, modified Rankin Scale, National Institutes of Health Stroke Scale, early neurological deterioration, acute ischemic stroke, reperfusion therapy, antiplatelet therapy, functional recovery, neurology, cerebral hemorrhage, stroke care, clinical trial analysis
News Source: Cassandra Pierce. (November 14, 2026). Alteplase Fails to Improve Minor Stroke Recovery While Increasing Bleeding Risk. Scienmag.



